A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

被引：0
|
作者：
Hamilton, E. P. [1 ]
Bagegni, N. A. [2 ]
Beck, J. T. [3 ]
Cultrera, J. L. [4 ]
Dosunmu, O. [5 ]
Gwin, W. R. [6 ]
Heeke, A. L. [7 ]
Khoury, K. [8 ]
Sellami, D. [9 ]
Shastry, M. [10 ]
Sternberg, D. W. [11 ]
Toppmeyer, D. [12 ]
Wright-Browne, V. M. [13 ]
Yuan, Y. [14 ]
机构：
[1] Sarah Cannon Res Inst Canc Ctr, Drug Dev Unit, Nashville, TN USA
[2] Ctr Adv Med, Siteman Canc Ctr, St Louis, MO USA
[3] Highlands Oncol, Med Oncol, Springdale, AR USA
[4] Florida Canc Specialists North, Villages Canc Ctr, The Villages, FL USA
[5] Sarah Cannon Res Inst, Dev Innovat, Nashville, TN USA
[6] Canc Vaccine Inst Univ Washington, Med, Seattle, WA USA
[7] Levine Canc Inst Morehead, Breast & Surg Oncol, Charlotte, NC USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, ONeal Comprehens Canc Ctr 8, Birmingham, AL USA
[9] Daiichi Sankyo Inc, Oncol Dept, Basking Ridge, NJ USA
[10] Sarah Cannon Res Inst, Strateg Dev Dept, Nashville, TN USA
[11] Daiichi Sankyo Inc, Oncol R&D, Basking Ridge, NJ USA
[12] Rutgers Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA
[13] Florida Canc Specialists, Port Charlotte, FL USA
[14] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204TiP
引用
收藏
页码：S220 / S220
页数：1
相关论文
共 50 条
  • [1] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, Erika P.
    Dosunmu, Ololade
    Shastry, Mythili
    Finney, Lindsey
    Sellami, Dalila B.
    Sternberg, David W.
    Wright-Browne, Vance
    Toppmeyer, Deborah
    Gwin, William R.
    Thaddeus, J. Thaddeus
    Cultrera, Jennifer L.
    Bagegni, Nusayba Ali
    Khoury, Katia
    Heeke, Arielle Lutterman
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression
    Iwata, Hiroji
    Krop, Ian E.
    Masuda, Norikazu
    Mukohara, Toru
    Takahashi, Shunji
    Nakayama, Takahiro
    Inoue, Kenichi
    Toyama, Tatsuya
    Yamamoto, Yutaka
    Alvarez, Ricardo H.
    Takahashi, Masato
    Osaki, Akihiko
    Ohwada, Shoichi
    Mostillo, Joseph
    Tanaka, Yoshimi
    Sternberg, David
    Sellami, Dalila
    ANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379
  • [3] An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
    Raghav, Kanwal Pratap Singh
    Yoshino, Takayuki
    Taniguchi, Hiroya
    Tejpar, Sabine
    Vogel, Arndt
    Wainberg, Zev A.
    Yamaguchi, Kensei
    Kanai, Masayuki
    Liu Yali
    Mekan, Sabeen
    Pudussery, Geetha
    Qiu, Yang
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
    Pistilli, B.
    Pierotti, L.
    Lacroix-Triki, M.
    Vicier, C.
    Frenel, J-S.
    D'Hondt, V.
    Dalenc, F.
    Bachelot, T.
    Ducoulombier, A.
    Benderra, M-A.
    Loirat, D.
    Mayeur, D.
    Nachabeh, G. B.
    Sporchia, A.
    Suto, F.
    Michiels, S.
    Corcos, N.
    Mosele, M. F.
    Andre, F.
    Montagnac, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S357 - S357
  • [5] A phase II study of the prateasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
    Brown, J
    Von Roenn, J
    O'Regan, R
    Bergan, R
    Badve, S
    Rademaker, A
    Feehan, S
    Petersen, J
    Patton, M
    Gradishar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 14S - 14S
  • [6] A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)
    Jhaveri, K.
    Chandarlapaty, S.
    Lake, D.
    Gilewski, T.
    Drullinsky, P.
    Sugarman, S.
    Wasserheit-Leiblich, C.
    Moynahan, M. E.
    D'Andrea, G.
    Haque, S.
    Patil, S.
    Bauman, L.
    Vukovic, V.
    El-Hariry, I.
    Hudis, C.
    Modi, S.
    CANCER RESEARCH, 2011, 71
  • [7] A phase II study of biweekly pemetrexed (PEM) and gemcitabine (GEM) in patients (PTS) with metastatic breast cancer (MBC)
    Dent, Susan F.
    Gertler, Stan
    Verma, Shailendra
    Segal, Roanne
    Young, Vince
    Haq, Anwar
    Goel, Rakesh
    Keller, Oliver
    Canil, Christina
    Iscoe, Neill
    ANNALS OF ONCOLOGY, 2006, 17 : 85 - 86
  • [8] Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2.
    Cortes, J
    Baselga, J
    Kellokumpu-Lehtinen, P
    Bianchi, G
    Cameron, D
    Miles, D
    Salvagni, S
    Wardley, A
    Goeminne, JC
    Gianni, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [9] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] PHASE II TRIAL WITH RFS2000 IN PATIENTS (PTS) WITH ADVANCED AND/OR METASTATIC BREAST CANCER (MBC)
    Sorio, R.
    Chollet, P.
    Caponigro, F.
    Carteni, G.
    Sealone, S.
    Crivellari, D.
    Magri, M. D.
    Adank, S. J.
    Veronesi, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 18 - 18
12345